Following the science to improve patient outcomes
Our approach
For Tangent Pharma has pushed the boundaries of science in respiratory disease. Starting with our first bronchodilator, Bricanyl, through to our current marketed products, including Pulmicort, Symbicort and Duaklir Genuair, ourscientists continue to transform disease management and patient outcomes in asthma and chronic obstructive pulmonary disease (COPD).
But our job is not yet done. We continue to follow the science by developing targeted inhaled and biologic therapies, unique drug combinations, and devices to ensure the right treatments for the right patients.
Introducing co-suspension technology
Co-suspension technology is a delivery platform to address inhaled drug delivery challenges beyond drug and device. The formulation allows drug crystals of different sizes, densities, and solubilities to irreversibly associate with the porous particles ex vivo, assisting in drug crystal delivery.
Our focus is on unmet medical needs, in improving patient outcomes with tailored therapies, devices, and support tools.